Industry Analysis Viral Conjunctivitis Pipeline Drugs Industrial Trend and Market Demand: (FST-100 and APD-209): Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
"Viral
Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry
Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
This
report analyzes the current and future prospects of the viral
conjunctivitis pipeline drugs market across major countries. Viral
conjunctivitis is a highly contagious disease; however, not a single
drug has been approved by the U.S. FDA to treat it. Hence, demand for
these drugs for viral conjunctivitis is likely to increase after
their expected launch.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=759850
The
research is a combination of primary and secondary research. Primary
research formed the bulk of our research efforts with information
collected from telephonic interviews and interactions via e-mails.
Secondary research involved study of company websites, annual
reports, press releases, stock analysis presentations, and various
international and national databases.
The
report provides estimated market size in terms of US$ Mn for each
drug for the period from expected launch to 2023, considering the
macro and micro environmental factors. Growth rates for each drug
within the market have been determined after a thorough analysis of
current scenario, demographics, epidemiological study, future trends,
competition with other pipeline drugs, and regulatory requirements.
The market report comprises an elaborate executive
summary, which includes a market snapshot that provides information
about various segments of the market. It also provides information
and data analysis of the market with respect to market segments based
on the drug and geographic analysis. Based on pipeline drug, the
market has been segmented into FST-100 and APD-209. Market size
estimations involved in-depth study of both the drugs and product
information. Additionally, market related factors such as product
innovation, number of viral conjunctivitis patients in various
countries, and expected launch date were taken into consideration
while estimating the market size. The report also provides the
compound annual growth rate (CAGR %) for each market segment for the
forecast period from expected launch to 2023.
Based on geography, the market has been analyzed
for major countries: the U.S., the U.K., Germany, Australia, Japan,
and Brazil. The market forecast for each of these countries has been
provided for the period from expected launch in the country to 2023,
along with their respective CAGRs for the forecast period from
expected launch to 2023. The countries are selected based on ongoing
clinical trial for FST-100 and APD-209.
A detailed qualitative analysis of factors
responsible for driving and restraining the market and opportunities
have been provided in the market overview section. This section of
the report also provides epidemiological data and patent analysis of
pipeline drugs, with a thorough analysis of the overall competitive
scenario in the viral conjunctivitis pipeline drugs market.
A list of recommendations has been provided for
new entrants to assist them in taking strategic initiatives to
establish a strong presence in the market. The report also profiles
major players in the market based on various attributes such as
company overview, financial overview, product portfolio, business
strategies, and recent developments. The viral conjunctivitis
pipeline drugs market is highly consolidated. Major companies
profiled in this market report are Adenovir Pharma AB, Allergan plc,
NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc.,
Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.
** The viral conjunctivitis pipeline drugs market
has been segmented as follows:
– Viral Conjunctivitis Pipeline Drugs
Market, by Drug
- FST-100
- APD-209
– Viral Conjunctivitis Pipeline Drugs
Market, by Country
- U.S.
- U.K.
- Germany
- Australia
- Japan
- Brazil
– Table
of Content
1. Preface
1.1. Report Description
1.2. Research Methodology
1.3. Assumptions
1.4. Market Segmentation
1.1. Report Description
1.2. Research Methodology
1.3. Assumptions
1.4. Market Segmentation
2. Executive Summary
2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
3. Viral Conjunctivitis Pipeline Drugs
Market – Industry Analysis
3.1. Introduction
3.1.1. Sign and Symptoms
3.1.2. Diagnosis
3.1.3. Management
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Large Unmet Needs
3.2.1.2. Strong Pipeline
3.2.2. Restraints
3.2.2.1. Low diagnosis rate
3.2.2.2. Self-Limiting Condition
3.2.3. Opportunity
3.2.3.1. Investment in Rigorous R&D Activities
3.2.3.2. Strengthen Commercialization Activities
3.3. Epidemiology
3.4. Patent Analysis of Pipeline Drugs
3.1. Introduction
3.1.1. Sign and Symptoms
3.1.2. Diagnosis
3.1.3. Management
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Large Unmet Needs
3.2.1.2. Strong Pipeline
3.2.2. Restraints
3.2.2.1. Low diagnosis rate
3.2.2.2. Self-Limiting Condition
3.2.3. Opportunity
3.2.3.1. Investment in Rigorous R&D Activities
3.2.3.2. Strengthen Commercialization Activities
3.3. Epidemiology
3.4. Patent Analysis of Pipeline Drugs
4. Market Segmentation – By
Pipeline Drug
4.1. Introduction
4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
4.4. Early Stage Preclinical Trials (Tabular Form)
4.1. Introduction
4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
4.4. Early Stage Preclinical Trials (Tabular Form)
5. Market Segmentation – By Country
5.1. Introduction
5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)
5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)
5.1. Introduction
5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)
5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)
6. Recommendations
7. Company Profiles
7.1. Adenovir Pharma AB
7.2. Allergan plc
7.3. NanoViricides, Inc.
7.4. Shire plc
7.5. NovaBay Pharmaceuticals, Inc.
7.6. Novartis AG
7.7. Panoptes Pharma GES.M.B.H.
7.8. NicOx S.A.
7.1. Adenovir Pharma AB
7.2. Allergan plc
7.3. NanoViricides, Inc.
7.4. Shire plc
7.5. NovaBay Pharmaceuticals, Inc.
7.6. Novartis AG
7.7. Panoptes Pharma GES.M.B.H.
7.8. NicOx S.A.
List of Table
TABLE 1 Viral Conjunctivitis Pipeline Drugs
Market: Market Snapshot
TABLE 2 Viral Conjunctivitis: Management
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023
TABLE 2 Viral Conjunctivitis: Management
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023
List of Chart
FIG. 1 Viral Conjunctivitis Pipeline Drugs Market
Share, by Geography, (Value %), 2023 (E)
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
Comments
Post a Comment